BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27597408)

  • 1. Design, synthesis, biological evaluation and molecular docking study on peptidomimetic analogues of XK469.
    Xia QH; Hu W; Li C; Wu JF; Yang L; Han XM; Shen YM; Li ZY; Li X
    Eur J Med Chem; 2016 Nov; 124():311-325. PubMed ID: 27597408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
    El-Adl K; El-Helby AA; Sakr H; Elwan A
    Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors.
    Ibrahim MK; Taghour MS; Metwaly AM; Belal A; Mehany ABM; Elhendawy MA; Radwan MM; Yassin AM; El-Deeb NM; Hafez EE; ElSohly MA; Eissa IH
    Eur J Med Chem; 2018 Jul; 155():117-134. PubMed ID: 29885574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers.
    Abbass EM; Khalil AK; Mohamed MM; Eissa IH; El-Naggar AM
    Bioorg Chem; 2020 Nov; 104():104255. PubMed ID: 32927130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors.
    Eissa IH; Metwaly AM; Belal A; Mehany ABM; Ayyad RR; El-Adl K; Mahdy HA; Taghour MS; El-Gamal KMA; El-Sawah ME; Elmetwally SA; Elhendawy MA; Radwan MM; ElSohly MA
    Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900123. PubMed ID: 31463953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and Discovery of Novel Quinoxaline Derivatives as Dual DNA Intercalators and Topoisomerase II Inhibitors.
    Eissa IH; El-Naggar AM; El-Sattar NEAA; Youssef ASA
    Anticancer Agents Med Chem; 2018; 18(2):195-209. PubMed ID: 28699490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinolino[3,4-b]quinoxalines and pyridazino[4,3-c]quinoline derivatives: Synthesis, inhibition of topoisomerase IIα, G-quadruplex binding and cytotoxic properties.
    Palluotto F; Sosic A; Pinato O; Zoidis G; Catto M; Sissi C; Gatto B; Carotti A
    Eur J Med Chem; 2016 Nov; 123():704-717. PubMed ID: 27521587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of 3-(benzazol-2-yl)quinoxaline derivatives as potent anticancer compounds: Privileged structure-based design, synthesis, and bioactive evaluation in vitro and in vivo.
    Liu QQ; Lu K; Zhu HM; Kong SL; Yuan JM; Zhang GH; Chen NY; Gu CX; Pan CX; Mo DL; Su GF
    Eur J Med Chem; 2019 Mar; 165():293-308. PubMed ID: 30685528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469).
    Hazeldine ST; Polin L; Kushner J; Paluch J; White K; Edelstein M; Palomino E; Corbett TH; Horwitz JP
    J Med Chem; 2001 May; 44(11):1758-76. PubMed ID: 11356111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
    My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ
    Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
    Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF
    Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and antitumor evaluation of 2,4,6-triaryl pyridines containing chlorophenyl and phenolic moiety.
    Thapa P; Karki R; Yun M; Kadayat TM; Lee E; Kwon HB; Na Y; Cho WJ; Kim ND; Jeong BS; Kwon Y; Lee ES
    Eur J Med Chem; 2012 Jun; 52():123-36. PubMed ID: 22503656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of amino-substituted benzo[f]pyrido[4,3-b] and pyrido[3,4-b]quinoxalines: a new class of antineoplastic agents.
    Nguyen CH; Fan E; Riou JF; Bissery MC; Vrignaud P; Lavelle F; Bisagni E
    Anticancer Drug Des; 1995 Jun; 10(4):277-97. PubMed ID: 7786395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors.
    Deady LW; Kaye AJ; Finlay GJ; Baguley BC; Denny WA
    J Med Chem; 1997 Jun; 40(13):2040-6. PubMed ID: 9207945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of (E)-2-(2-arylhydrazinyl)quinoxalines, a promising and potent new class of anticancer agents.
    Rodrigues FA; Bomfim Ida S; Cavalcanti BC; Pessoa Cdo Ó; Wardell JL; Wardell SM; Pinheiro AC; Kaiser CR; Nogueira TC; Low JN; Gomes LR; de Souza MV
    Bioorg Med Chem Lett; 2014 Feb; 24(3):934-9. PubMed ID: 24398294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XK469, a selective topoisomerase IIbeta poison.
    Gao H; Huang KC; Yamasaki EF; Chan KK; Chohan L; Snapka RM
    Proc Natl Acad Sci U S A; 1999 Oct; 96(21):12168-73. PubMed ID: 10518594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Part I: Synthesis, cancer chemopreventive activity and molecular docking study of novel quinoxaline derivatives.
    Galal SA; Abdelsamie AS; Tokuda H; Suzuki N; Lida A; Elhefnawi MM; Ramadan RA; Atta MH; El Diwani HI
    Eur J Med Chem; 2011 Jan; 46(1):327-40. PubMed ID: 21145626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular modeling studies and synthesis of novel quinoxaline derivatives with potential anticancer activity as inhibitors of c-Met kinase.
    Abbas HA; Al-Marhabi AR; Eissa SI; Ammar YA
    Bioorg Med Chem; 2015 Oct; 23(20):6560-72. PubMed ID: 26420384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and antitumor activities of a series of novel quinoxalinhydrazides.
    Grande F; Aiello F; Grazia OD; Brizzi A; Garofalo A; Neamati N
    Bioorg Med Chem; 2007 Jan; 15(1):288-94. PubMed ID: 17085054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS.
    Gao H; Yamasaki EF; Chan KK; Shen LL; Snapka RM
    Mol Pharmacol; 2003 Jun; 63(6):1382-8. PubMed ID: 12761349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.